Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial

Gregg W. Stone, Mark Midei, William Newman, Mark Sanz, James B. Hermiller, Jerome Williams, Naim Farhat, Ronald Caputo, Nicholas Xenopoulos, Robert Applegate, Paul Gordon, Roseann M. White, Krishnankutty Sudhir, Donald E. Cutlip, John L. Petersen

Research output: Contribution to journalArticlepeer-review

282 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science